association

Full identifier: http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association

Assigned to 1 class:

Minted in Nanopublication

 RAYyW5a_et comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RAYyW5a_et... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-12T13:30:39.307+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAYyW5a_et... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAYyW5a_et... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAYyW5a_et... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:30:39.307Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
elaprase is indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and older in patients 16 months to 5 years of age no data are available to demonstrate improvement in disease related symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age see use in specific populations 8 4 elaprase is a hydrolytic lysosomal glycosaminoglycan gag specific enzyme indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and older in patients 16 months to 5 years of age no data are available to demonstrate improvement in disease related symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age 1
Leoni Bücken
2021-06-12T11:30:39.307Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:30:39.307Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:30:39.307Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:30:39.307Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:30:39.307Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:30:39.307Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:30:39.307Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)